Andrea Kay
Publications by Year
Research Areas
Renal cell carcinoma treatment, COVID-19 Clinical Research Studies, Fibroblast Growth Factor Research, SARS-CoV-2 and COVID-19 Research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial(2008)3,002 cited
- → Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer(2003)2,533 cited
- → Phase 3 trial of everolimus for metastatic renal cell carcinoma(2010)1,140 cited
- → Gaucher Disease(1992)337 cited
- → Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer(2013)312 cited
- → Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy(2009)248 cited
- → Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer(2005)225 cited
- → Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma(2010)210 cited
- → 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.(1992)169 cited
- → Enzyme replacement therapy for Gaucher disease(1991)168 cited